In Depth 9 Apr 2025 Cystic fibrosis: is the next blockbuster a gene therapy? Learn about the biotechs progressing their gene therapies for cystic fibrosis and why it might just be the breakthrough that patients need. April 9, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Nov 2024 Cystic fibrosis: Five biotechs breathing life into the therapeutic space In this article, we take a look at five biotechs developing potentially transformative medicines to treat this genetic disease. November 7, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 2 May 2024 New treatments for cystic fibrosis: boosting life expectancy Discover how cystic fibrosis treatments are extending life expectancy, with recent advancements set to increase it by 75% by next year. May 2, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 4 Apr 2024 Seven diseases CRISPR technology could cure Here are some of the diseases that scientists aim to tackle using CRISPR technology, testing its possibilities and limits as a medical tool. April 4, 2024 - 11 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Anoat raises funds to tackle cystic fibrosis Anoat Therapeutics, a French preclinical stage biotechnology company specialized in cystic fibrosis (CF), has raised €2 million ($2.17 million) in seed funding from AdBio partners. Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. Anoat Therapeutics’ goal is to bring a transformative and mutation-agnostic […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2023 Inspire Biotherapeutics launches to target lung diseases through gene therapy Inspire Biotherapeutics Inc., an emerging Canadian biotech company with a mission to create gene therapies for monogenic and acquired diseases of the lung, is set to move its novel lung tropic AAV gene therapy into clinical validation. The AAVenger platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types […] March 16, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2023 Nanite receives funding to deliver genetic therapies to the lungs Nanite Inc. has announced an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technologies for the lung. This builds on the $6 million seed financing recently announced by the company. One of the most significant challenges in developing new therapies for patients with cystic fibrosis is effective drug […] March 15, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Renexxion goes to FDA with cystic fibrosis drug Renexxion Ireland Limited has opened an investigational new drug (IND) application with the U.S Food and Drug Administration (FDA) for naronapride for the treatment of GI motility disorders in patients with cystic fibrosis (CF). This is a first step towards conducting clinical trials of the drug candidate in CF patients. Naronapride, post approval, could be […] January 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 A biotech boom manifesting real results in rare pediatric diseases By Bob Coughlin, managing director, life sciences, JLL For the last two years, the pandemic has resulted in the explosive growth in life sciences. The world watched in awe and anticipation as biotech successfully raced to develop vaccines, therapeutics and diagnostics for Covid-19. It has been a good moment for an industry that deserves such […] November 14, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 FDA gives ok to Krystal Biotech cystic fibrosis clinical trial U.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application. The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to […] August 2, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Cystic fibrosis in the crosshairs as Carbon Biosciences launches with $38M funding Carbon Biosciences, a Longwood Fund founded biotech company developing parvovirus-derived gene therapies, has launched with $38 million of financing led by Agent Capital. Agent is joined by Longwood Fund, Astellas Venture Management LLC, the Cystic Fibrosis Foundation, Solasta Ventures, University of Tokyo Innovation Platform (UTokyoIPC), and Camford Capital. Massachusetts-based Carbon is harnessing novel parvovirus vectors […] June 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Expert Advice 27 May 2020 Why Listening to Patient Organizations is Key in Drug Development As the biotech industry flourishes and therapies become more targeted and personalized, the need for drug developers to interact with patients is increasing as well. While patient organizations took a backseat in the past, they are continuously gaining importance in drug development today. Nowadays, talking with patient organizations has become paramount for successful drug development, […] May 27, 2020 - 11 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email